# Belgian Medical Genomics Initiative (BeMGI): genetic testing and reimbursement in Belgium

Gert Matthijs Center for Human Genetics, University of Leuven, Belgium


Marc Abramowicz
Hôpital Erasme, Université Libre de Bruxelles, Belgium

## Overview

- Organisation of genetic services in Belgium
  - Reimbursement system
- (Rare Disease Plan)
- (Cancer)
- (Plan for the) introduction of 'genomics'
  - Prenatal CGH arrays
  - Targeted panels, exomes
- Europe
  - Recommendations on genetic services (Council of Europe)
  - Guidelines for diagnostic NGS testing (EuroGentest)

## Genetic testing in Belgium

- Public healthcare system
- 8 genetic centres (regulated by law since 1987)
  linked to academic hospitals ('private-non-profit')
  4 in Flanders, 4 in Wallonia
- Specific reimbursement system for genetic tests since 1988 wonderfully simple and efficient



## Genetic centres in Belgium

All (8) universities/university hospitals have a "center for human/medical genetics".

### Funded in part:

- by the regional governments "for service to the patients and public, and for research (development)"
- by the national health care system on the basis of clinical/diagnostic activities
- by research grants

## Reimbursement

- Specific reimbursement system since 1988
  - Cytogenetic, molecular and biochemical tests
  - Prenatal tests
- Since 2013:
  - Stratified reimbursment of (molecular) genetic tests
  - Reimbursement for consultations (counseling)
  - Reimbursement for samples sent abroad

!!!! Accreditation (ISO 15189) of the lab is an obligation !!!!

"A.R. 22.7.1988" (en vigueur 1.8.1988)

"SECTION II. Examens génétiques.

Art. 33. § 1<sup>er</sup>. Sont considérés comme prestations qui requièrent la qualification de médecin visé au § 2 :

Examens génétiques :


Caryogramme autres cas que ceux prévus à la prestation		
n° 588652 - 588663) <b>€ 327</b>	В	8000
Détermination de la chromatine sexuelle	В	209
Caryogramme sur culture de cellules amniotiques € 327	В	8000
Mise en culture de cellules amniotiques en vue d'un		
caryogramme (prestation n° 588652 - 588663) et/ou d'un		
dosage d'enzymes intracellulaires (prestation n° 588733 -		
588744) (ne peut être portée en compte qu'une fois même si		
les deux prestations n°s 588652 - 588663 et 588733 -		
588744 ont dû être effectuées)	В	3000
Recherche d'anomalies génétiques par les méthodes		
d'hybridation de fragments d'A.D.N. € 327	В	8000

## Reimbursement

- The unique reimbursement system has been critized.
- € 327 (\$ 444) for CF-testing?
- € 327 (\$ 444) for BRCA testing!
- 2001: initiative to stratify the tests
- 2013: new regulation in place

Budget: approx. 40 M EUR in 2013 (appox. 54 M USD) for 11.099.554 inhabitants

### **Genetic testing – national costs - Belgium**





## Reimbursement

- Karyotype (€295) , FISH (€184), CGH arrays (€579)
- DNA test: a stratified system

Simple	Hemochromatosis	€ 78	\$ 105
Frequent	CF, fragile X	€ 155	\$ 211
Typical	Duchenne, MD,	€ 357	\$ 485
Complex	hemophilia, LDLR,	€ 558	\$ 758
Very complex	BRCA, LQT, + PANELS	€ 1,377	\$ 1,871

- Prenatal test (€465)
- Biochemistry (€61 € 620)
- Patient pays only € 8,68 (\$ 12) !
- No reimbursement for exomes/genomes (yet)

## An exemplary system?

- All genetic centres combine clinical and laboratory activities
- Accredited diagnostic labs are closely associated with the academic research centres
- Parsimonious use of the national 'envelope' for testing
- Stratified system allows flexibility
- Development of national guidelines
- Recent initiative for reimbursement of exomes (genomes)
- System challenged by commercial companies
  - Disconnected from the needs (patient and population)
  - No genetic counselling
- Belgian Medical Genomics Initiative (BeMGI)

## **Belgian Medical Genomics Initiative**

- a network funded by the Interuniversity Attraction Poles (IAP) programme of the Belgian Federal Science Policy Office (BELSPO)
- Research, standardization, education, ...



















## A national plan for exomes

To create the best possible framework for exome sequencing in a clinical context



## European context



on the impact of genetics on the organisation of health care services and training of health professionals

## Guidelines for diagnostic next generation sequencing



- Diagnostic routing, diagnostic utility
- 'Scoring system' for gene panels and exomes
- Instructions for 'incidental findings'
- Etc.



#### **Executive Committee**

Scientific Secretariat





#### Scientific Committees

- 1 representative per funding body
- 1 representative per group of funders (accumulative funding)
- representatives of umbrella organizations of patient advocacy groups
- the chairs of the Scientific Committees

Diagnostics

Interdisciplinary

Therapies

15 members with balanced representation of scientists, patients, industry, etc.



#### **Working Groups**



Ontologies and diseases prioritization

Sequencing

Model systems

Genome/Phenome

Ethics and Governance

Biobanks

Registries and Natural history

Bioinformatics and data sharing Representatives of funded projects or patients organisations, experts, etc.

Biomarkers for disease progression and therapies responses Chemically-derived products including repurposing

Biotechnology-derived products including cell-& gene-based therapies


Orphan drugdevelopment and regulatory processes

## Additional slides

Not for presentation, for information only

## Molecular diagnostics in Europe

Genetic testing laboratory affiliations



Source: IPTS/JRC-EC (Ibarreta et al. Towards quality assurance and harmonization of genetic testing services in the EU. Report EUR20977, 2003)

# Recommendation of the Committee of Ministers to member states.

CM/Rec (2010)11

"from specialised genetic services to genetics as an integral part of general health services"

"strengthen genetic services to maximise the benefits of genetic applications in health care for all patients"

"genetic services should incorporate clinical and laboratory facilities"

Democracy

Rule of Law

Organisation

47 Countries

Topics

Newsroom

# Recommendation of the Committee of Ministers to member states.

CM/Rec (2010)11

...

- 5. Primary care providers should have the necessary skills to assess the family history, recognise genetic risks, discuss with patients and relatives the implications of genetic disorders and to appropriately refer them to genetic services.
- 6. The recommendations set out in point 5 also apply to specialists in other fields of medicine.

. . .



Human Rights

**Democracy** 

Rule of Law

Organisation •

47 Countries

Tonice

Newsroom

# Recommendation of the Committee of Ministers to member states.

CM/Rec (2010)11

• • •

"...systematic assessment of the quality, effectiveness and efficiency of genetic services.

- developing and sharing standards
- clinical practice guidelines
- clinical protocols at the European level."

. . .



#### **EUCERD**

The European Union Committee of Experts on Rare Diseases is charged with aiding the European Commission with the preparation and implementation of Community activities in the field of rare diseases, in cooperation and consultation with the specialised bodies in Member States, the relevant European authorities in the fields of research and public health action and other relevant stakeholders acting in the field. Read more





2013 edition of the State of the Art of RD Activities report now online



8th EUCERD meeting: New recommendations adopted



IRDiRC delivers a successful and inspiring conference: a common



New EUCERD Recommendation on RD European Reference



## HARMONIZING GENETIC TESTING ACROSS EUROPE

Home Genetic Laboratories Health Professionals Patients, Public & Policy I




Season's greetings and best wishes for 2014 from the EuroGentest team.

#### What is EuroGentest?

EuroGentest is a project funded by the European Commission to harmonize the process of genetic testing, from sampling to counseling, across Europe. The ultimate goal is to ensure that all aspects of genetic testing are of **high quality** thereby providing **accurate and reliable results for the benefit of the patients.** More...

#### For specific groups







Patients, Public & Policy

#### Workshops



Prepare for accreditation or improve your current quality management system by participating in our interactive workshops.

#### Clinical Utility Gene Cards



Clear and concise documents with good practice information for disease specific genetic tests.

#### Patient Leaflets



Download leaflets with information on genetic testing for patients and their family in your own language.

#### Newsletters



Monthly highlights of news and events on quality and genetic testing.

About EuroGentest

About Us FAQ

Linked in

Policies

<u>Privacy</u>

<u>Disclaimer</u>

<u>Accessibility</u>

Standards WSC THILL WSC CORD

Advertising







HOME

ABOUT US »

**ACTIVITIES** »

RARE DISEASES RESEARCH »

RESEARCH FUNDING »

**NEW THERAPIES** 

NEWS & MEDIA »

Search...

HELPFUL LINKS »

IRDIRC PRIVATE WEBSITE



#### SPOTLIGHT ON INITIATIVES



#### FDA awards USD 14 million to 15 rare disease projects

The U.S. Food and Drug Administration (FDA) announced it has awarded 15 grants worth more than \$14 million altogether which will aim to improve the course of development of products that will be valuable to patients with rare diseases. The grant applications were reviewed by...

F.... A.--!--



